Oncology (All Articles)
RCT: Endoscopic surgery improves survival compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma
28 Feb, 2021 | 20:45h | UTC
CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma
26 Feb, 2021 | 08:31h | UTCOriginal study: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine
Integrated palliative and oncology care for patients receiving treatment for acute myeloid leukemia
26 Feb, 2021 | 08:25h | UTCOriginal article: Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Randomized trial: Oral Azacitidine maintenance therapy for acute myeloid leukemia in first remission
26 Feb, 2021 | 08:23h | UTCOral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Maintenance Oral Azacitidine for Patients With AML in First Remission: QUAZAR AML-001 Trial – The ASCO Post
ASCO Guideline: Management of dyspnea in advanced cancer
24 Feb, 2021 | 02:10h | UTCManagement of Dyspnea in Advanced Cancer: ASCO Guideline – Journal of Clinical Oncology
Commentary on Twitter (thread – click for more)
1/ How can we better manage dyspnea in people with advanced cancer?
Wonderful to see this new @ASCO Guideline out.
Led by Drs. @DrDavidHui and @campbell_meg #supponc #pallonc
Full text: https://t.co/qbdhzbibKw pic.twitter.com/f2Qf6GswvK
— Arjun Gupta (@guptaarjun90) February 23, 2021
SR: Delays and disruptions in cancer health care due to COVID-19 pandemic
24 Feb, 2021 | 02:46h | UTCCommentary: COVID-19 Pandemic Caused Delays in Cancer Care – DocWire News
Commentary on Twitter
Delays & Disruptions in #Cancer HealthCare Due to #COVID19 Pandemic – A health system Perspective:
Interruptions & disruptions in:
🏥77%, facility-level
🔗79%, supply chain
🩺60%, personnel availabilityFind more from @FroitbergM at:https://t.co/wGtpNW5Zrm@ASCO_pubs 👏👏 pic.twitter.com/R3jlzAsfRG
— Dario Trapani (@darioT_) February 23, 2021
Gastroesophageal reflux disease is linked with higher risks of larynx and esophageal cancers
24 Feb, 2021 | 02:00h | UTC
Guidelines in the management of CNS tumors
23 Feb, 2021 | 01:09h | UTCGuidelines in the management of CNS tumors – Journal of Neuro-Oncology
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
21 Feb, 2021 | 21:43h | UTCClinical practice guidelines for BRCA1 and BRCA2 genetic testing – European Journal of Cancer
Commentary on Twitter
BRCA1 and BRCA2 genetic testing- Clinical practice guidelineshttps://t.co/bpdXf70PnW pic.twitter.com/i6O0br35ap
— K Pavithran (@drkpavithran) February 15, 2021
Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update
21 Feb, 2021 | 21:47h | UTC
Review: Diagnosis and treatment of metastatic colorectal cancer
19 Feb, 2021 | 02:07h | UTCDiagnosis and Treatment of Metastatic Colorectal Cancer: A Review – JAMA (free for a limited period)
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
19 Feb, 2021 | 02:04h | UTC
Review: Optimal supportive care for patients with metastatic breast cancer according to their disease progression phase
18 Feb, 2021 | 02:35h | UTC
RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%
18 Feb, 2021 | 02:34h | UTC
Commentary on Twitter
Phase 3 trial suggests #cemiplimab could be used as new first-line monotherapy option for patients with advanced non-small-cell #lungcancer with PD-L1 of at least 50%—it improved overall & progression-free survival compared with chemotherapy. Read https://t.co/O06Of6wx07 pic.twitter.com/KtQ24lEoR5
— The Lancet (@TheLancet) February 17, 2021
Editorial: Bundled payment models in oncology
17 Feb, 2021 | 01:16h | UTCEditorial: Bundled Payment Models in Oncology: Learning to Think in New Ways – JCO Oncology Practice
Counterpoint: Oncology Care Model: A Herculean Effort With Fixable Fatal Flaws – JCO Oncology Practice
Review: Breast cancer in adolescent and young adult women under the age of 40 years
17 Feb, 2021 | 01:13h | UTCBreast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years – JCO Oncology Practice
M-A: Role of diet in colorectal cancer incidence
17 Feb, 2021 | 01:12h | UTC
Preliminary study suggests there may be a role for prostate cancer screening with magnetic resonance imaging
16 Feb, 2021 | 01:50h | UTCCommentaries: Short MRI Protocol Could Be Alternative for Prostate Cancer Follow-Up – Diagnostic Imaging AND Short MRI exam shows promise for prostate cancer screening follow-up – AuntMinnie (free registration required)
Commentary on Twitter
A handy infographic of our recently published research
Full paper is open access and free for all 🔬📜🙌
👉https://t.co/xDlz1A4kjR@eldredevans @JAMAOnc @EmilyD_stats @SageOfLondon1 @Connor_Urol @ImperialSandC @LondonProstate1 @Francy_lif @ProfPadhani @HemmySokhi pic.twitter.com/cEwSCv4NXy— Imperial Prostate (@IP_London) February 14, 2021
RCT: Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer
16 Feb, 2021 | 01:44h | UTCShort-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial – The Lancet Oncology (link to abstract – $ for full-text)
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
15 Feb, 2021 | 00:49h | UTC
RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
15 Feb, 2021 | 00:36h | UTCLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival was significantly longer with lenvatinib plus pembrolizumab than with sunitinib.
— NEJM (@NEJM) February 13, 2021
RCT: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
15 Feb, 2021 | 00:34h | UTCEnfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma
15 Feb, 2021 | 00:32h | UTCA comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress
Long-term data: No difference in cardiovascular mortality or morbidity with transdermal estradiol vs. LHRH agonists for androgen suppression in prostate cancer
15 Feb, 2021 | 00:31h | UTCTransdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme – The Lancet (link to abstract – $ for full-text)
RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer
15 Feb, 2021 | 00:29h | UTC[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today